EUVIMEDEUVIMED entdecken
Crossref

Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma

Jie Ma, Siqi Zhang, Nianhui Yang, Jingjie Shang, Xin Gao, Jiahui Chen, Huiyi Wei, Yinlong Li, Hui Zeng, Hao Xu, Jinghao Wang, Steven H Liang und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-01 · 52 (2) · 599-610

DOI: 10.1007/s00259-024-06907-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 11.09.2024. Verfasst von Jie Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharma…. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Positron-Emission Tomography, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Guangzhou Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Multiple myeloma (MM) is characterized by the uncontrolled proliferation of monoclonal plasma cells (PC) in the bone marrow (BM). B-cell maturation antigen (BCMA) is predominantly expressed in malignant plasma cells, and associated with the proliferation, survival, and progression of various myeloma cells. Given these important roles, BCMA emerges as an ideal target antigen for MM therapy. However, effective stratification of patients who may benefit from targeted BCMA therapy and real-time monitoring the therapeutic efficacy poses significant clinical challenge. This study aims to develop a BCMA targeted diagnostic modality, and preliminarily explore its potential value in the radio-immunotherapy of MM. EXPERIMENTAL DESIGN: Using zirconium-89 (89Zr, t1/2 = 78.4 h) for labeling the BCMA-specific antibody, the BCMA-targeting PET tracer [89Zr]Zr-DFO-BCMAh230430 was prepared. The EC50 values of BCMAh230430 and DFO-BCMAh230430 were determined by ELISA assay. BCMA expression was assessed in four different tumor cell lines (MM.1S, RPMI 8226, BxPC-3, and KYSE520) through Western blot and flow cytometry. In vitro binding affinity was determined by cell uptake studies of [89Zr]Zr-DFO-BCMAh230430 in these tumor cell lines. For in vivo evaluation, PET imaging and ex vivo biodistribution studies were conducted in tumor-bearing mice to evaluate imaging performance and systemic distribution of [89Zr]Zr-DFO-BCMAh230430. Immunochemistry analysis was performed to detect BCMA expression in tumor tissues, confirming the specificity of our probe. Furthermore, we explored the anti-tumor efficacy of Lutetium-177 labeled BCMA antibody, [177Lu]Lu-DTPA-BCMAh230430, in tumor bearing-mice to validate its radioimmunotherapy potential. RESULTS: The radiolabeling of [89Zr]Zr-DFO-BCMAh230430 and [177Lu]Lu-DTPA-BCMAh230430 showed satisfactory radiocharacteristics, with a radiochemical purity exceeding 99%. ELISA assay results revealed closely aligned EC50 values for BCMAh230430 and DFO-BCMAh230430, which are 57 pM and 67 pM, respectively. Western blot and flow cytometry analyses confirmed the highest BCMA expression level. Cell uptake data indicated that MM.1S cells had a total cellular uptake (the sum of internalization and surface binding) of 38.3% ± 1.53% for [89Zr]Zr-DFO-BCMAh230430 at 12 h. PET imaging of [89Zr]Zr-DFO-BCMAh230430 displayed radioactive uptake of 7.71 ± 0.67%ID/g in MM.1S tumors and 4.13 ± 1.21%ID/g in KYSE520 tumors at 168 h post-injection (n = 4) (P < 0.05), consistent with ex vivo biodistribution studies. Immunohistochemical analysis of tumor tissues confirmed higher BCMA expression in MM.1S tumors xenograft compared to KYSE520 tumors. Notably, [177Lu]Lu-DTPA-BCMAh230430 showed some anti-tumor efficacy, evidenced by slowed tumor growth. Furthermore, no significant difference in body weight was observed in MM.1S tumor-bearing mice over 14 days of administration with or without [177Lu]Lu-DTPA-BCMAh230430. CONCLUSIONS: Our study has successfully validated the essential role of [89Zr]Zr-DFO-BCMAh230430 in non-invasively monitoring BCMA status in MM tumors, showing favorable tumor uptake and specific binding affinity to MM tumors. Furthermore, our research revealed, as a proof-of-concept, the effectiveness of [177Lu]Lu-DTPA-BCMAh230430 in radioimmunotherapy for MM tumors. In conclusion, we present a novel BCMA antibody-based radiotheranostic modality that holds promise for achieving efficient and precise MM diagnostic and therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaB-Cell Maturation AntigenPositron-Emission TomographyAntibodies, MonoclonalAnimalsMiceHumansZirconiumCell Line, TumorRadioisotopesTissue Distribution

Stichwörter der Autor:innen

89ZrB-cell maturation antigen (BCMA)ImmunoPETMultiple myelomaPositron emission tomography (PET)

Substanzen

B-Cell Maturation AntigenZirconiumZirconium-89RadioisotopesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzho…
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
  • Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
  • Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA.
  • Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
  • The Guangzhou Key Laboratory of Basic and Translational Research On Chronic Disease, Guangzhou, 510630, China.

ORCID-Profile: Lu Wang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Planning Project of Guangdong Province
  • Guangzhou Science and Technology Program

Zitieren

APA

Ma, J., Zhang, S., Yang, N., Shang, J., Gao, X., Chen, J., Wei, H., Li, Y., Zeng, H., Xu, H., Wang, J., Liang, S. H., Wang, R., Hu, K., & Wang, L. (2025). Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 52(2), 599-610. https://doi.org/10.1007/s00259-024-06907-3

Vancouver

Ma J, Zhang S, Yang N, Shang J, Gao X, Chen J, et al. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(2):599-610. doi:10.1007/s00259-024-06907-3

BibTeX
@article{Ma2025,
  author = {Ma, Jie and Zhang, Siqi and Yang, Nianhui and Shang, Jingjie and Gao, Xin and Chen, Jiahui and Wei, Huiyi and Li, Yinlong and Zeng, Hui and Xu, Hao and Wang, Jinghao and Liang, Steven H and Wang, Rui and Hu, Kuan and Wang, Lu},
  title = {Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {2},
  pages = {599--610},
  doi = {10.1007/s00259-024-06907-3}
}
Kostenlos starten →